Principaux résultats et analyse des parts de marché des inhibiteurs de l'EGFR-TKI pour le cancer du poumon non à petites cellules avancé d'ici 2025-2031
EGFR-TKI for Advanced NSCLC Market Report Analysis
EGFR-TKI for Advanced NSCLC Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Beta pharma Ltd
- Actiza pharmaceuticals
- AstraZeneca
- Sun Pharmaceuticals
- Roche
- Teva Pharmaceutical Industries
- Armas Pharmaceuticals, Inc
- Boehringer Ingelheim
- Rewine Pharmaceutical
Regional Overview
- Amérique du Nord
- Europe
- Asie-Pacifique
- Amérique du Sud et centrale
- Moyen-Orient et Afrique
Market Segmentation
By Type
- Géfitinib
- Erlotinib
- Afatinib
- Icotinib
By Type de thérapie
- monothérapie
- thérapie combinée
By Utilisateur final
- hôpitaux
- centres de cancérologie
- autres
By Géographie
- Amérique du Nord
- Europe
- Asie-Pacifique
- Amérique du Sud et Centrale
Get Free Sample For